The EPIVER Randomized Controlled Trial

• Status: Recruiting
• Trial end date: 2023-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The trial aims to estimate the efficacy and safety of the intracoronary administration of adrenalin, verapamil, as well as their combination compared to standard treatment in patients with STEMI and refractory coronary no-reflow despite conventional treatment during percutaneous coronary intervention (PPCI)

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tomsk National Research Medical Center of the Russian Academy of Sciences
• Treatments: Epinephrine; Epinephryl borate; Racepinephrine; Verapamil

Criteria

Inclusion Criteria:

• patients with ST-elevation myocardial infarction

• Infarct-related artery TIMI flow grade 0-2 during the interventional procedure after the initial opening of the vessel.

• Written the informed consent to participate in research

Exclusion Criteria:

• Unable to undergo or contra-indications for MRI or SPECT